Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2026 17:00 ET | Source: Sapu Bioscience, LLC

Sapu Bioscience Expands International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

SAN DIEGO, CA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Sapu Bioscience today announced advancements in its global IP portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform,...
February 12, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) and Sapu Bioscience today announced key advancements in its global intellectual...
November 30, 2022 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials

AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
November 08, 2022 07:33 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas

AGOURA HILLS, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), a developer of treatments for rare and orphan indications,...
August 22, 2022 09:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS

Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, AGOURA HILLS,...
August 17, 2022 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Participating at Biotechgate Digital Partnering

AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
June 15, 2022 07:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention

AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
March 03, 2022 08:01 ET | Source: Oncotelic Therapeutics, Inc.

Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit

AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief...
January 19, 2022 09:05 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting at BiotechGate Digital Partnering

OT-101 is Oncotelic’s RNA Therapeutic Against TGF-βOT-101 has completed over six clinical trials against solid tumors with good efficacyOT-101 is currently undergoing a phase 1b trial in combination...
November 16, 2021 08:15 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...